HQI Earnings

HQI reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 8.50M against an estimate of 8.10M, resulting in a 4.9% surprise. The EPS was 0.24, surpassing the expected 0.14 by 71.43%. The stock experienced a 15.53% price change on the earnings day and a 16.49% change over the next five days, reflecting market reactions to the results.

Following HQI's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 15.53% on the day of the release. Over the subsequent five days, it saw a 16.49% change. Historically, HQI's stock price tends to shift by an average of -1.44% in the 10 days leading up to earnings and -5.93% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate HQI's annual revenue to reach 7.50M, while the EPS is projected at 0.12. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between HQI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HQI's stock price typically moves by -1.44% in the 10 days before its earnings and -5.93% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.12 and revenue of 7.50M.

The earnings call reveals a decline in key financial metrics such as revenue, franchise royalties, and system-wide sales, reflecting challenges in the staffing industry. Despite cost management efforts and a share repurchase program, the overall sentiment remains negative due to decreasing financial performance. The Q&A section did not present any significant positive developments to offset these concerns. The lack of acquisitions and minimal impact of the MRI transaction further contribute to a negative outlook, likely leading to a stock price decline of -2% to -8% over the next two weeks.